Expert Interview
Discussing the use of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies.
Ticker(s): NVSInstitution: New Mexico Cancer Center
- Medical Director of Radiation Oncology at the New Mexico Cancer Center & Assistant Professor of Medicine and the University of New Mexico.
- Treats 7 patients per month with mCRPC and has 6 patients receiving Pluvicto every month.
- Research and clinical interest in radiation oncology.
Can you discuss what your patients' experience have been on Pluvicto?
Added By:How does Pluvicto compare to other therapies in the mCRPC space?
Added By:If you had to rate your level of excitement on a 1 to 10 scale for the potential of Pluvicto, what would it be and why?
Added By:Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
